FI940336A0 - Yhdistelmävasta-aineita ihmisterapiaan - Google Patents
Yhdistelmävasta-aineita ihmisterapiaanInfo
- Publication number
- FI940336A0 FI940336A0 FI940336A FI940336A FI940336A0 FI 940336 A0 FI940336 A0 FI 940336A0 FI 940336 A FI940336 A FI 940336A FI 940336 A FI940336 A FI 940336A FI 940336 A0 FI940336 A0 FI 940336A0
- Authority
- FI
- Finland
- Prior art keywords
- recombinant antibodies
- human therapy
- therapy
- human
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73506491A | 1991-07-25 | 1991-07-25 | |
US73506491 | 1991-07-25 | ||
US85628192A | 1992-03-23 | 1992-03-23 | |
US85628192 | 1992-03-23 | ||
PCT/US1992/006194 WO1993002108A1 (en) | 1991-07-25 | 1992-07-24 | Recombinant antibodies for human therapy |
US9206194 | 1992-07-24 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI940336A0 true FI940336A0 (fi) | 1994-01-24 |
FI940336A FI940336A (fi) | 1994-03-10 |
FI117703B FI117703B (fi) | 2007-01-31 |
Family
ID=27112830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI940336A FI117703B (fi) | 1991-07-25 | 1994-01-24 | Menetelmä kimeerisen vasta-aineen tuottamiseksi ja sitä koodaava nukleiinihappo |
Country Status (24)
Country | Link |
---|---|
EP (3) | EP0605442B1 (fi) |
JP (1) | JP3048640B2 (fi) |
KR (1) | KR0137806B1 (fi) |
AP (1) | AP307A (fi) |
AT (2) | ATE327331T1 (fi) |
AU (1) | AU673499B2 (fi) |
BG (1) | BG62656B1 (fi) |
BR (1) | BR9206313A (fi) |
CA (1) | CA2114015C (fi) |
CZ (1) | CZ289472B6 (fi) |
DE (2) | DE69233628T2 (fi) |
DK (2) | DK0605442T3 (fi) |
ES (2) | ES2265005T3 (fi) |
FI (1) | FI117703B (fi) |
HU (2) | HUT70272A (fi) |
IL (1) | IL102640A0 (fi) |
MY (1) | MY121185A (fi) |
NO (1) | NO318097B1 (fi) |
NZ (1) | NZ243706A (fi) |
OA (1) | OA09879A (fi) |
PT (1) | PT100735B (fi) |
RO (1) | RO116404B1 (fi) |
SK (2) | SK285046B6 (fi) |
WO (1) | WO1993002108A1 (fi) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
EP0523949B1 (en) * | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Production of antibodies |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
GB2294267B (en) | 1993-06-03 | 1996-11-20 | Therapeutic Antibodies Inc | Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies |
US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
ATE195428T1 (de) * | 1994-04-26 | 2000-09-15 | Kanebo Ltd | Arznei für rheumatoide arthritis |
JP3323508B2 (ja) * | 1994-10-25 | 2002-09-09 | グラクソ グループ リミテッド | Cd23に対する結合物質 |
HUT77342A (hu) * | 1994-12-07 | 1998-03-30 | F.Hoffmann-La Roche Ag. | Immunoszupresszív aktivitással rendelkező monoklonális antitest fragmensek |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
US7033589B1 (en) | 1997-02-20 | 2006-04-25 | Biogen Idec Ma Inc. | γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6893636B2 (en) | 1997-02-20 | 2005-05-17 | Biogen Idec Ma Inc. | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics |
US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
JP2002512776A (ja) * | 1998-04-28 | 2002-05-08 | スミスクライン・ビーチャム・コーポレイション | 免疫原性の低下したモノクローナル抗体 |
GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
HU228180B1 (hu) | 1998-08-11 | 2013-01-28 | Biogen Idec Inc | Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára |
DK1616572T3 (da) | 1998-11-09 | 2010-12-06 | Biogen Idec Inc | Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi |
AU777970C (en) | 1999-05-07 | 2006-08-17 | F. Hoffman-La Roche Ag | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
US6852510B2 (en) | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
KR100868594B1 (ko) * | 2000-07-03 | 2008-11-13 | 갈라 디자인, 인크. | 다수의 통합 벡터를 함유하는 숙주 세포 |
EP1297168A2 (en) | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expression vectors |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
US20050101012A1 (en) | 2001-03-12 | 2005-05-12 | Gerold Schuler | CD4+CD25+ regulatory T cells from human blood |
EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
TWI327597B (en) | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
US20040038304A1 (en) | 2002-03-28 | 2004-02-26 | Gala Design, Inc. | Antibody libraries |
US8222033B2 (en) | 2002-08-12 | 2012-07-17 | Argos Therapeutics, Inc. | CD4+CD25− T cells and Tr1-like regulatory T cells |
ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
CA2543631A1 (en) * | 2003-11-07 | 2005-05-26 | Amgen Inc. | Monkey immunoglobulin sequences |
PL1687066T3 (pl) | 2003-11-14 | 2013-01-31 | Brigham & Womens Hospital Inc | Sposoby modulowania odporności |
SG151292A1 (en) | 2004-03-30 | 2009-04-30 | Glaxo Group Ltd | Immunoglobulins |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
US8962278B2 (en) * | 2005-08-03 | 2015-02-24 | Ibio Inc. | Compositions and methods for production of immunoglobulins |
CA2619244A1 (en) * | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
ZA200802246B (en) * | 2005-08-15 | 2009-09-30 | Arana Therapeutics Ltd | Engineered antibodies with new world primate framework regions |
WO2007070948A1 (en) * | 2005-12-20 | 2007-06-28 | Arana Therapeutics Limited | Anti-inflammatory dab |
JP5259423B2 (ja) | 2006-02-01 | 2013-08-07 | セファロン・オーストラリア・ピーティーワイ・リミテッド | ドメイン抗体構築物 |
AU2007283463B2 (en) | 2006-08-11 | 2012-04-26 | Csl Limited | Treatment of pulmonary disease conditions |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
US8323653B2 (en) | 2006-09-08 | 2012-12-04 | Medimmune, Llc | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
ES2658239T3 (es) | 2006-10-19 | 2018-03-08 | Csl Limited | Antagonistas de anticuerpos de alta afinidad del receptor alfa 1 de interleucina-13 |
JP2010507365A (ja) | 2006-10-19 | 2010-03-11 | メルク アンド カンパニー インコーポレイテッド | 抗IL−13Rα1抗体およびその使用 |
US20090143288A1 (en) | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
US20090022720A1 (en) | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
EP2331140B1 (en) | 2008-08-11 | 2018-07-04 | Nektar Therapeutics | Multi-arm polymeric alkanoate conjugates |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
EP3208282A1 (en) | 2010-11-30 | 2017-08-23 | F. Hoffmann-La Roche AG | Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier |
WO2012088445A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds |
WO2012088422A1 (en) | 2010-12-22 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of taxane-based compounds |
WO2012166555A1 (en) | 2011-05-27 | 2012-12-06 | Nektar Therapeutics | Water - soluble polymer - linked binding moiety and drug compounds |
WO2013064471A1 (de) * | 2011-10-31 | 2013-05-10 | Jan-Niklas Keltsch | Einhändig bedienbare verpackung |
US10940204B2 (en) | 2015-07-31 | 2021-03-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
WO2017066719A2 (en) | 2015-10-14 | 2017-04-20 | Research Institute At Nationwide Children's Hospital | Hu specific interfering agents |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
EP3565834A1 (en) | 2017-01-04 | 2019-11-13 | The Research Institute at Nationwide Children's Hospital | Antibody fragments for the treatment of biofilm-related disorders |
JP2020513838A (ja) | 2017-01-04 | 2020-05-21 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Dnabiiワクチンおよび強化された活性を有する抗体 |
KR20240038146A (ko) | 2017-01-30 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
WO2018147915A1 (en) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
JP2020513808A (ja) | 2017-03-15 | 2020-05-21 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
AU2019355194A1 (en) | 2018-10-05 | 2021-04-22 | Research Institute At Nationwide Children's Hospital | Compositions and methods for enzymatic disruption of bacterial biofilms |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
CA3145385A1 (en) | 2019-07-08 | 2021-01-14 | Steven D. Goodman | Antibody compositions for disrupting biofilms |
JP2023527926A (ja) | 2020-06-04 | 2023-06-30 | バイオインベント インターナショナル アーべー | 静脈内投与と関連する抗体耐容性の改善 |
JP2024509944A (ja) | 2021-03-09 | 2024-03-05 | バイオインヴェント インターナショナル アーベー | 抗体の新規の組み合わせ及びその使用 |
WO2023161448A1 (en) | 2022-02-24 | 2023-08-31 | Abnomx Bv | Human-like target-binding proteins |
TW202336033A (zh) | 2022-03-07 | 2023-09-16 | 瑞典商生物創新國際有限公司 | 抗體之新穎組合及用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0523949B1 (en) * | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Production of antibodies |
-
1992
- 1992-07-24 DE DE69233628T patent/DE69233628T2/de not_active Revoked
- 1992-07-24 EP EP92917108A patent/EP0605442B1/en not_active Expired - Lifetime
- 1992-07-24 NZ NZ243706A patent/NZ243706A/en unknown
- 1992-07-24 HU HU9400201A patent/HUT70272A/hu unknown
- 1992-07-24 RO RO94-00095A patent/RO116404B1/ro unknown
- 1992-07-24 AU AU24255/92A patent/AU673499B2/en not_active Ceased
- 1992-07-24 AT AT02012106T patent/ATE327331T1/de active
- 1992-07-24 EP EP02012106A patent/EP1266965B1/en not_active Revoked
- 1992-07-24 ES ES02012106T patent/ES2265005T3/es not_active Expired - Lifetime
- 1992-07-24 IL IL102640A patent/IL102640A0/xx not_active IP Right Cessation
- 1992-07-24 DK DK92917108T patent/DK0605442T3/da active
- 1992-07-24 DK DK02012106T patent/DK1266965T3/da active
- 1992-07-24 SK SK88-94A patent/SK285046B6/sk not_active IP Right Cessation
- 1992-07-24 SK SK5059-2005A patent/SK285960B6/sk not_active IP Right Cessation
- 1992-07-24 WO PCT/US1992/006194 patent/WO1993002108A1/en active IP Right Grant
- 1992-07-24 CA CA002114015A patent/CA2114015C/en not_active Expired - Fee Related
- 1992-07-24 BR BR9206313A patent/BR9206313A/pt not_active Application Discontinuation
- 1992-07-24 ES ES92917108T patent/ES2196002T3/es not_active Expired - Lifetime
- 1992-07-24 JP JP5503072A patent/JP3048640B2/ja not_active Expired - Fee Related
- 1992-07-24 AT AT92917108T patent/ATE237638T1/de not_active IP Right Cessation
- 1992-07-24 KR KR1019940700217A patent/KR0137806B1/ko not_active IP Right Cessation
- 1992-07-24 DE DE69233011T patent/DE69233011T2/de not_active Expired - Fee Related
- 1992-07-24 EP EP06010708A patent/EP1715045A3/en not_active Withdrawn
- 1992-07-24 CZ CZ1994149A patent/CZ289472B6/cs not_active IP Right Cessation
- 1992-07-25 MY MYPI92001327A patent/MY121185A/en unknown
- 1992-07-27 AP APAP/P/1992/000413A patent/AP307A/en active
- 1992-07-27 PT PT100735A patent/PT100735B/pt not_active IP Right Cessation
-
1994
- 1994-01-21 NO NO19940219A patent/NO318097B1/no not_active IP Right Cessation
- 1994-01-24 BG BG98411A patent/BG62656B1/bg unknown
- 1994-01-24 OA OA60460A patent/OA09879A/en unknown
- 1994-01-24 FI FI940336A patent/FI117703B/fi active IP Right Grant
-
1995
- 1995-06-29 HU HU95P/P00595P patent/HU211881A9/hu unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI940336A (fi) | Yhdistelmävasta-aineita ihmisterapiaan | |
NO980915L (no) | Rekombinante anti-CD4-antistoff egnet for human terapi | |
NO924395L (no) | Rekombinante menneske-faktor viii derivater | |
DK19991D0 (da) | Proteinpraeparationer | |
DE69230061D1 (de) | Künstliches immunoglobulin-bindendes protein | |
DK64592D0 (da) | Peptider til terapeutisk behandling | |
DK162890D0 (da) | Polypeptid | |
FI930674A0 (fi) | Terapeutiska aemnen | |
FI934588A0 (fi) | Insulinlik vaextfaktor bindande protein haerstammande fraon maenniskoben | |
FI931071A (fi) | Terapeutiska aemnen | |
DE69228669T2 (de) | Proteinsequenzierung | |
DK0519976T3 (da) | Neutrofilstimulerende peptider | |
FI920701A (fi) | Anordning foer terapeutisk tryckbehandling | |
ZA925615B (en) | Recombinant antibodies for human therapy | |
DK149591D0 (da) | Proteinpraeparat | |
DK111891D0 (da) | Polypeptid | |
DK106390D0 (da) | Polypeptid | |
DK185590D0 (da) | Polypeptid | |
DK236190D0 (da) | Polypeptid | |
DK147891D0 (da) | Proteinpraeparat | |
DK494189D0 (da) | Polypeptid | |
KR900016676U (ko) | 송아지 분만 보조장치 | |
SE9202223L (sv) | Madrass eller liknande för smärtindikering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 117703 Country of ref document: FI |